Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Ends Gene Therapy Trial Reporting Requirements In Reg Streamlining Move

Executive Summary

Trial protocols, annual reports, and adverse event reports on gene therapies now only go to US FDA, a signal that the products can be regulated like other drugs and biologics.

You may also be interested in...



Gene Therapy Guidance From US FDA Likely Needs Updating Sooner Rather Than Later

CBER Director Peter Marks says the "half-life" for the existing six gene therapy guidances likely is two to three years due to the fast pace of scientific discovery.

Gene Therapy Oversight To Be Streamlined By US FDA, NIH

Streamlining adverse event reports among reform ideas; NIH's Recombinant DNA Advisory Committee likely to drop review of more routine protocols.

CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors

INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel